Rakuten Investment Management Inc. Buys 49,096 Shares of Becton, Dickinson and Company $BDX

Rakuten Investment Management Inc. bought a new position in Becton, Dickinson and Company (NYSE:BDX) in the 3rd quarter, Holdings Channel.com reports. The firm bought 49,096 shares of the medical instruments supplier’s stock, valued at approximately $8,934,000.

A number of other institutional investors and hedge funds have also made changes to their positions in BDX. Maryland Capital Advisors Inc. raised its holdings in Becton, Dickinson and Company by 13,900.0% during the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 139 shares in the last quarter. Meeder Asset Management Inc. lifted its position in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares during the period. Main Street Group LTD purchased a new stake in Becton, Dickinson and Company in the 1st quarter valued at approximately $29,000. Bell Investment Advisors Inc purchased a new stake in Becton, Dickinson and Company in the 2nd quarter valued at approximately $29,000. Finally, Kelleher Financial Advisors acquired a new position in Becton, Dickinson and Company during the 2nd quarter worth approximately $30,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 6,907 shares of company stock worth $1,269,128 in the last quarter. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Stock Up 1.8%

Shares of NYSE BDX opened at $213.05 on Friday. The stock has a market capitalization of $58.70 billion, a price-to-earnings ratio of 16.09, a price-to-earnings-growth ratio of 14.10 and a beta of 0.22. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $214.78. The firm has a 50-day moving average price of $187.69 and a 200 day moving average price of $170.23. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.11 billion. During the same period in the prior year, the business posted $3.96 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Equities research analysts anticipate that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its board has initiated a stock repurchase program on Thursday, November 5th that permits the company to repurchase 10,000,000 outstanding shares. This buyback authorization permits the medical instruments supplier to purchase up to 3.6% of its stock through open market purchases. Share buyback programs are typically an indication that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be paid a dividend of $1.06 per share. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. The ex-dividend date of this dividend is Thursday, December 10th. This represents a $4.24 annualized dividend and a dividend yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Becton, Dickinson and Company News Summary

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BDX reported adjusted Q4 EPS of $4.15, above analysts’ roughly $4.07 estimate, and revenue of $5.3 billion, up 5.4% year over year and ahead of expectations. For FY2026, free cash flow rose 42.5% to $2.9 billion. BD fiscal 2026 results
• Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share, marking its 55th consecutive annual increase, and authorized an additional 10 million share repurchases. These actions may support investor returns and signal confidence in cash generation. Dividend and repurchase announcement
• Positive Sentiment: Evercore ISI raised its price target to $230 from $210, providing a favorable analyst signal. Evercore ISI price-target update
• Negative Sentiment: The main concern is FY2027 guidance: reports characterized the revenue-growth outlook as subdued and the overall outlook as largely in line with expectations. This tempered the positive reaction to the Q4 beat and has put pressure on BDX shares. Coverage of FY2027 guidance

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Royal Bank Of Canada increased their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. Jefferies Financial Group reissued a “buy” rating and issued a $242.00 price target on shares of Becton, Dickinson and Company in a report on Thursday. TD Cowen lifted their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Wolfe Research initiated coverage on Becton, Dickinson and Company in a report on Tuesday, October 20th. They set an “outperform” rating on the stock. Finally, Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Becton, Dickinson and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $187.20.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.